If reopening the economy after the prolonged shutdown was the end of the beginning, then the successful development of vaccines and therapeutic antibodies has the potential to be the beginning of the end.

In a Public England Health study, Siemens Healthineers’ COV2T antibody test was the only assay found to meet both sensitivity and specificity requirements of the MHRA.

After leaving the field of antimicrobials 20 years ago because other areas offered better returns, 23 pharma companies and the Novo Foundation have launched a US$1bn fund to fight antimicrobial resistance (AMR).

Leiden-based coagulant developer VarmX NV has closed a €32m Series B financing to push clinical development of VMX-C001, a venom-based modified recombinant Factor X.

Richard Sachse started at the beginning of July as new Chief Medical Officer at Sotio a.s.

A challenge whose success lies in efficient process management and digital development! The times of digitalisation and Industry 4.0 do not stop at the production of medical cannabis for the pharmaceutical industry. The combination of IT systems and blockchain-based processes allows the value-added chain to be automated and the data generated to be mapped in a tamper-proof manner.

Viennese APEIRON Biologics and MaxCyte Inc have entered into licensing agreement covering the use of Maxcyte’s electroporation platform for APN401 development.

After closing the business merging with blank check company Arya Sciences Acquisition Corp, Immatics Inc has been listed on Nasdaq.

A new insulin formulation allows patients with diabetes to more quickly manage their blood sugar levels during mealtimes.

Data from the UK’s RECOVERY trial demonstrate there was no clinical benefit from use of lopinavir-ritonavir in hospitalised COVID-19 patients.